Your browser is no longer supported. Please, upgrade your browser.
Settings
XNCR Xencor, Inc. daily Stock Chart
XNCR [NASD]
Xencor, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own1.00% Shs Outstand58.97M Perf Week5.12%
Market Cap2.35B Forward P/E- EPS next Y-2.02 Insider Trans-55.68% Shs Float47.73M Perf Month13.22%
Income-40.20M PEG- EPS next Q-0.49 Inst Own84.60% Short Float6.09% Perf Quarter-1.29%
Sales40.00M P/S58.70 EPS this Y-196.10% Inst Trans-0.33% Short Ratio10.53 Perf Half Y12.68%
Book/sh9.51 P/B4.19 EPS next Y-30.30% ROA-11.80% Target Price43.86 Perf Year88.01%
Cash/sh4.61 P/C8.65 EPS next 5Y- ROE-13.40% 52W Range19.50 - 48.38 Perf YTD81.66%
Dividend- P/FCF- EPS past 5Y-11.30% ROI-9.20% 52W High-17.69% Beta1.78
Dividend %- Quick Ratio5.50 Sales past 5Y30.30% Gross Margin- 52W Low104.21% ATR2.32
Employees114 Current Ratio5.50 Sales Q/Q- Oper. Margin- RSI (14)54.50 Volatility5.74% 6.65%
OptionableYes Debt/Eq0.00 EPS Q/Q111.20% Profit Margin- Rel Volume0.59 Prev Close38.96
ShortableNo LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume275.78K Price39.82
Recom1.60 SMA208.74% SMA503.52% SMA20012.13% Volume163,921 Change2.21%
Sep-10-18Resumed BTIG Research Buy $56
Mar-28-18Resumed Leerink Partners Outperform $36
Mar-02-17Reiterated Wedbush Outperform $27 → $33
Mar-02-17Initiated Instinet Neutral $21
Oct-04-16Initiated Piper Jaffray Overweight
Dec-22-15Initiated Canaccord Genuity Buy $20
Aug-05-15Reiterated MLV & Co Buy $22 → $29
Feb-12-15Reiterated Oppenheimer Outperform $22 → $28
Jan-28-15Reiterated MLV & Co Buy $18 → $22
Jul-11-14Initiated Oppenheimer Outperform $22
Nov-08-18 09:01AM  Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors PR Newswire
Nov-06-18 05:40PM  Edited Transcript of XNCR earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +6.83%
05:06AM  Xencor: 3Q Earnings Snapshot Associated Press
Nov-05-18 04:01PM  Xencor Reports Third Quarter 2018 Financial Results PR Newswire
Nov-01-18 09:01AM  Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire +15.59%
Oct-30-18 10:33AM  Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline Zacks
Oct-29-18 04:01PM  Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018 PR Newswire -5.69%
Oct-25-18 08:50AM  Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.86%
Oct-05-18 08:01AM  Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting PR Newswire
Sep-25-18 08:01AM  Xencor to Participate in Upcoming Investor Conferences PR Newswire -5.47%
Sep-18-18 06:32AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Aug-08-18 08:30AM  New Research Coverage Highlights Goldman Sachs BDC, PTC, Weingarten Realty Investors, Astronics, Xencor, and Chemours Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Aug-07-18 04:50PM  This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation Investor's Business Daily +7.49%
Aug-06-18 05:45PM  Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:41PM  Xencor: 2Q Earnings Snapshot Associated Press
04:01PM  Xencor Reports Second Quarter 2018 Financial Results PR Newswire
02:30PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-18 08:01AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Jul-30-18 08:01AM  Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018 PR Newswire
Jul-18-18 06:00AM  Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors PR Newswire
Jul-16-18 08:20AM  Today's Research Reports on Trending Tickers: REGENXBIO and Xencor ACCESSWIRE
Jul-12-18 04:00PM  Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors PR Newswire
Jun-18-18 11:45AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
May-31-18 04:01PM  Xencor to Present at Upcoming Investor Conferences PR Newswire
May-09-18 03:56PM  Edited Transcript of XNCR earnings conference call or presentation 7-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-07-18 04:19PM  Xencor: 1Q Earnings Snapshot Associated Press
04:01PM  Xencor Reports First Quarter 2018 Financial Results PR Newswire
12:30PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
May-04-18 07:55AM  Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
May-02-18 08:00AM  Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference PR Newswire
Apr-30-18 08:00AM  Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018 PR Newswire
Apr-18-18 09:00AM  Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting PR Newswire
Apr-11-18 06:31PM  What Do Analysts Think About Xencor Incs (NASDAQ:XNCR) Earnings Trajectory? Simply Wall St.
01:46PM  Harry Boxers five biotech stocks to watch MarketWatch
Apr-04-18 09:15PM  3 Top Biotech Stocks to Buy in April Motley Fool
Mar-30-18 03:21PM  Edited Transcript of XNCR earnings conference call or presentation 27-Feb-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-21-18 08:00AM  Xencor to Present at 17th Annual Needham Healthcare Conference PR Newswire
Mar-20-18 07:44PM  Xencor Announces Pricing of Public Offering of Common Stock PR Newswire
Mar-19-18 04:09PM  Xencor, Inc. Announces Proposed Public Offering of Common Stock PR Newswire
Mar-03-18 04:43PM  What Do Investors Need To Know About Xencor Incs (NASDAQ:XNCR) Growth? Simply Wall St.
Mar-01-18 08:30AM  Consolidated Research: 2018 Summary Expectations for Sonic Automotive, Xencor, Gevo, OSI, Buckeye Partners, and Glatfelter Fundamental Analysis, Key Performance Indications GlobeNewswire
Feb-27-18 06:27PM  Xencor reports 4Q loss Associated Press
04:01PM  Xencor Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire
12:40PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
Feb-22-18 08:00AM  Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors PR Newswire +5.01%
Feb-20-18 08:00AM  Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018 PR Newswire
Feb-07-18 08:00AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Jan-05-18 08:00AM  Xencor Announces 2018 Priorities and Expected Milestones PR Newswire
07:45AM  New Research: Key Drivers of Growth for Portola Pharmaceuticals, Kindred Healthcare, Interface, Apogee Enterprises, Sonic Automotive, and Xencor Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-02-18 08:07AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Dec-28-17 12:46PM  ETFs with exposure to Xencor, Inc. : December 28, 2017 Capital Cube
Dec-27-17 08:40AM  Xencor, Inc. :XNCR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube
Dec-19-17 08:00AM  Xencor Appoints Richard Ranieri to Board of Directors PR Newswire
Dec-14-17 02:48PM  Xencor, Inc. Value Analysis (NASDAQ:XNCR) : December 14, 2017 Capital Cube
Dec-13-17 07:42AM  Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : December 13, 2017 Capital Cube
Dec-05-17 08:00AM  Xencor Receives Milestone Payment from Amgen PR Newswire
Nov-27-17 08:07AM  Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : November 27, 2017 Capital Cube
08:05AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Nov-15-17 08:04AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Nov-13-17 02:16PM  Edited Transcript of XNCR earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 08:16AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit +5.36%
Nov-08-17 08:00AM  Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting PR Newswire
Nov-07-17 05:14PM  Xencor reports 3Q loss Associated Press
04:01PM  Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update PR Newswire
12:00PM  Xencor, Inc. to Host Earnings Call ACCESSWIRE
Nov-04-17 07:30PM  Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting PR Newswire
Nov-01-17 08:00AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Oct-31-17 08:00AM  Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 PR Newswire
Oct-23-17 11:50AM  Xencor, Inc. Value Analysis (NASDAQ:XNCR) : October 23, 2017 Capital Cube
Oct-20-17 04:00PM  Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting PR Newswire
08:27AM  Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : October 20, 2017 Capital Cube
Oct-02-17 08:04AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Sep-25-17 08:19AM  Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : September 25, 2017 Capital Cube
08:05AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Sep-20-17 08:00AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Sep-19-17 06:52PM  ETFs with exposure to Xencor, Inc. : September 19, 2017 Capital Cube
Sep-18-17 12:41PM  Xencor, Inc. :XNCR-US: Earnings Analysis: Q2, 2017 By the Numbers : September 18, 2017 Capital Cube
Sep-11-17 08:58AM  Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : September 11, 2017 Capital Cube
Aug-22-17 08:02AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Aug-18-17 08:02AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Aug-16-17 11:27PM  Xencor, Inc. Value Analysis (NASDAQ:XNCR) : August 17, 2017 Capital Cube
Aug-13-17 05:51AM  Edited Transcript of XNCR earnings conference call or presentation 7-Aug-17 8:30pm GMT Thomson Reuters StreetEvents
Aug-11-17 08:05AM  See what the IHS Markit Score report has to say about Xencor Inc. Markit
Aug-07-17 10:55PM  Xencor reports 2Q loss Associated Press
04:01PM  Xencor Reports Second Quarter 2017 Financial Results PR Newswire
Aug-03-17 09:48AM  Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : August 3, 2017 Capital Cube
Aug-02-17 08:00AM  Xencor to Present at Upcoming Investor Conferences PR Newswire
Jul-31-17 08:00AM  Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017 PR Newswire
Jul-06-17 08:19AM  Xencor, Inc. breached its 50 day moving average in a Bullish Manner : XNCR-US : July 6, 2017 Capital Cube
Jun-16-17 08:00AM  Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017 PR Newswire
Jun-12-17 02:36PM  ETFs with exposure to Xencor, Inc. : June 12, 2017 Capital Cube
Jun-09-17 10:16AM  Xencor, Inc. :XNCR-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 Capital Cube
Jun-08-17 08:00AM  Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology PR Newswire
May-30-17 08:00AM  Xencor to Present at Jefferies 2017 Global Healthcare Conference PR Newswire
May-23-17 05:00PM  Worst-Performing Gurus' Stocks GuruFocus.com
May-11-17 08:00AM  Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease PR Newswire
May-10-17 05:44PM  Edited Transcript of XNCR earnings conference call or presentation 9-May-17 8:30pm GMT Thomson Reuters StreetEvents -7.97%
May-09-17 05:24PM  Xencor reports 1Q loss Associated Press
04:01PM  Xencor Reports First Quarter 2017 Financial Results PR Newswire
03:00PM  Investor Network: Xencor, Inc. to Host Earnings Call Accesswire
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug, that in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; and AMG424, a bispecific CD38 x CD3 preclinical candidate for various myeloma. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104, which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. to develop and commercialize bispecific and other Fc engineered antibody drug candidates using its proprietary XmAb technologies and drug candidates, as well as MorphoSys Ag to develop and commercialize bispecific antibody product candidates; license agreement with Amgen Inc. to develop and commercialize bispecific antibody product candidates; and development and manufacturing services agreement with Catalent Pharma Solutions LLC. Xencor, Inc.was founded in 1997 and is headquartered in Monrovia, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Foster Paul AChief Medical OfficerSep 17Option Exercise11.0540,000442,00044,952Sep 18 04:28 PM
Foster Paul AChief Medical OfficerSep 17Sale46.0340,0001,841,2084,952Sep 18 04:28 PM
STAFFORD JOHN S III10% OwnerSep 14Sale48.051,00048,0545,017,848Sep 18 04:04 PM
Foster Paul AChief Medical OfficerAug 17Option Exercise11.053,65940,4328,611Aug 17 06:20 PM
Foster Paul AChief Medical OfficerAug 17Sale40.103,659146,7264,952Aug 17 06:20 PM
Foster Paul AChief Medical OfficerAug 16Option Exercise11.0520,739229,16625,691Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 16Sale41.1020,739852,3734,952Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 15Option Exercise11.051061,1715,058Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 15Sale41.101064,3574,952Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 14Option Exercise11.0515,496171,23120,448Aug 16 07:31 PM
Foster Paul AChief Medical OfficerAug 14Sale41.1115,496636,9804,952Aug 16 07:31 PM
Baracchini Edgardo JrChief Business OfficerAug 13Option Exercise11.0512,734140,71112,941Aug 13 07:59 PM
Baracchini Edgardo JrChief Business OfficerAug 13Sale40.3512,734513,874207Aug 13 07:59 PM
Baracchini Edgardo JrChief Business OfficerAug 10Sale40.0328,9831,160,045207Aug 13 07:59 PM
Desjarlais John RSr. V.P., Research & CSOAug 10Sale40.0314,867595,09288,098Aug 10 06:36 PM
Desjarlais John RSr. V.P., Research & CSOAug 09Option Exercise4.2535,000148,750123,098Aug 10 06:36 PM
Baracchini Edgardo JrChief Business OfficerAug 09Option Exercise11.0537,266411,78937,473Aug 13 07:59 PM
Desjarlais John RSr. V.P., Research & CSOAug 09Sale40.6120,133817,629102,965Aug 10 06:36 PM
Baracchini Edgardo JrChief Business OfficerAug 09Sale40.358,283334,19829,190Aug 13 07:59 PM
STAFFORD JOHN S III10% OwnerJul 17Sale41.2436,5001,505,2605,018,848Jul 17 04:08 PM
STAFFORD JOHN S III10% OwnerJul 16Sale40.6726,8881,093,5355,055,348Jul 17 04:08 PM
STAFFORD JOHN S III10% OwnerJul 13Sale41.9748,3122,027,6845,082,236Jul 17 04:08 PM
STAFFORD JOHN S III10% OwnerJul 12Sale39.5558,0002,293,9005,130,548Jul 12 05:26 PM
STAFFORD JOHN S III10% OwnerJul 11Sale39.6330,0071,189,1775,188,548Jul 12 05:26 PM
STAFFORD JOHN S III10% OwnerJul 10Sale39.8950,2932,006,1885,218,555Jul 12 05:26 PM
STAFFORD JOHN S III10% OwnerJun 20Sale40.0592,7793,715,7995,261,348Jun 20 04:28 PM
STAFFORD JOHN S III10% OwnerJun 19Sale39.77103,4544,114,3665,354,127Jun 20 04:28 PM
STAFFORD JOHN S III10% OwnerJun 18Sale39.8853,7672,144,2285,457,581Jun 20 04:28 PM
Dahiyat Bassil IPresident and CEOJun 15Option Exercise4.2550,000212,500343,067Jun 15 08:11 PM
Dahiyat Bassil IPresident and CEOJun 15Sale40.5150,0002,025,690293,067Jun 15 08:11 PM
Kuch John JSr. Vice President & CFOJun 13Option Exercise4.2535,853152,37592,482Jun 15 05:35 PM
Kuch John JSr. Vice President & CFOJun 13Sale41.6425,0001,040,94556,629Jun 15 05:35 PM
Baracchini Edgardo JrChief Business OfficerMar 15Option Exercise0.5940,00023,60040,000Mar 16 06:34 PM
Baracchini Edgardo JrChief Business OfficerMar 15Sale30.8940,0001,235,7440Mar 16 06:34 PM
Baracchini Edgardo JrChief Business OfficerMar 05Option Exercise0.5910,0005,90010,000Mar 05 06:45 PM
Baracchini Edgardo JrChief Business OfficerMar 05Sale29.5810,000295,8400Mar 05 06:45 PM
Baracchini Edgardo JrChief Business OfficerMar 02Option Exercise0.5910,0005,90010,000Mar 05 06:45 PM
Baracchini Edgardo JrChief Business OfficerMar 02Sale29.6010,000295,9660Mar 05 06:45 PM
Baracchini Edgardo JrChief Business OfficerFeb 27Option Exercise0.5920,00011,80020,000Mar 01 08:32 PM
Baracchini Edgardo JrChief Business OfficerFeb 27Sale29.6420,000592,8480Mar 01 08:32 PM
Baracchini Edgardo JrChief Business OfficerFeb 22Option Exercise0.598,0694,7618,069Feb 23 07:18 PM
Foster Paul AChief Medical OfficerFeb 22Option Exercise0.5910,0005,90012,419Feb 22 08:47 PM
Foster Paul AChief Medical OfficerFeb 22Sale26.0310,000260,3002,419Feb 22 08:47 PM
Baracchini Edgardo JrChief Business OfficerFeb 22Sale26.008,069209,7940Feb 23 07:18 PM
Foster Paul AChief Medical OfficerFeb 16Option Exercise0.595,0002,9507,419Feb 16 06:25 PM
Foster Paul AChief Medical OfficerFeb 16Sale25.015,000125,0502,419Feb 16 06:25 PM
STAFFORD JOHN S III10% OwnerDec 14Buy20.843,00062,5055,511,348Dec 14 05:00 PM
STAFFORD JOHN S III10% OwnerDec 12Buy20.726,215128,7755,508,348Dec 14 05:00 PM
STAFFORD JOHN S III10% OwnerNov 28Buy19.8610,025199,0975,502,133Nov 28 06:00 PM
STAFFORD JOHN S III10% OwnerNov 24Buy19.855,349106,1785,492,108Nov 28 06:00 PM